Status:
COMPLETED
Pyrotinib Plus Vinorelbine in HER2+ Metastatic Breast Cancer Patients
Lead Sponsor:
Fudan University
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
To evaluate the patterns and treatment outcomes of pyrotinib plus vinorelbine in the real world.
Eligibility Criteria
Inclusion
- woman, age \> 18 years old
- diagnosed with HER2 +Metastatic Breast Cancer
- pyrotinib plus vinorelbine for at least one cycle, starting from 2018.05-2020.05
- available medical history
Exclusion
- medical history was incomplete
Key Trial Info
Start Date :
May 15 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2021
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT04517305
Start Date
May 15 2018
End Date
May 15 2021
Last Update
June 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032